Eli Lilly and Company revised earnings guidance for the full year 2021. Earnings per share for 2021 are now expected to be in the range of $6.38 to $6.48 as compared to previous guidance of $6.73 to $6.93 per share. Revenue to be between $27.2 billion and $27.6 billion as compared to previous guidance of $26.8 to $27.4 billion.